ISA 201

Drug Profile

ISA 201

Alternative Names: Hespecta; HPV E-Six Peptide Conjugated To AMPLIVANT®; HPV16 E6 Peptide Conjugated To AMPLIVANT®; HPV16 peptides AMPLIVANT® vaccine; ISA201; SLP AMPLIVANT® head and neck cancer vaccine

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ISA Pharmaceuticals
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Head and neck cancer; Human papillomavirus infections

Most Recent Events

  • 28 Aug 2017 Phase-I/II development is ongoing in the Netherlands (NCT02821494)
  • 26 Feb 2015 Phase-I/II clinical trials in Human papillomavirus infections and Head and neck cancer in Netherlands (SC)
  • 14 May 2014 Preclinical trials in Human papillomavirus infections and Cancer in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top